公司资料
Verrica Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- VRCA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
4.89 USD (-1.61%)
收盘价
最后更新: 2026年8月17日
99.5M USD
市值
股价为何变动
As of Aug 17, 2026, VRCA closed down 1.61% at $4.89. No new same-company headline was identified in the current news window.
公司概览
Medical Dermatology
Verrica Pharmaceuticals develops and commercializes treatments for dermatologic diseases, including viral skin conditions and non-melanoma skin cancers.
YCANTH for Molluscum
YCANTH is a drug-device combination containing a controlled formulation of cantharidin in a single-use applicator. It is the first FDA-approved, healthcare-professional-administered treatment for molluscum contagiosum in adults and children two years of age and older.
Common-Wart Expansion
Verrica is evaluating YCANTH in the global pivotal COVE-2 and COVE-3 Phase 3 studies for common warts. The program is intended to extend the product into a substantially larger dermatology population.
VP-315 Skin-Cancer Program
VP-315, or ruxotemitide, is a licensed oncolytic peptide being prepared for Phase 3 development in basal cell carcinoma. The broader license also covers other non-melanoma skin cancers, including squamous cell carcinoma.
未来催化剂
- Topline results from the global Phase 3 YCANTH program in common warts in mid-2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。